Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Food Effect of BIBB 515 BS in Healthy Subjects
NCT02266498Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jun 1998
- Primary completion
- Jul 1998
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of BIBB 515 in hypercholesterolemia (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum concentration of the analyte in plasma up to 48 hours, Time to reach maximum concentration of the analyte in plasma up to 48 hours and 8 more. Started Jun 1998; status: completed.
02
Drugs
BIBB 515
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT02266498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266498.